Trastuzumab Emtansine Improves Long-Term ... which made research into ... Patients With Heart Disease May Be at Increased Risk for Advanced Breast Cancer Jan. 2, 2025 — Patients diagnosed ...

Soriot also highlighted to performance of Farxiga (dapagliflozin), AZ's SGLT2 inhibit for diabetes, heart failure and chronic ... new HER2 drug Enhertu (trastuzumab deruxtecan) almost doubling ...

That's when India's cancer burden is expected to rise from 26.7 million disability-adjusted life years or DALYs—the sum of healthy life lost to a disease—in 2021 to 29.8 million in 2025 ...

We've made significant strides in our oncology and infectious disease programs ... which enables potential combination strategies with trastuzumab-based therapies in an earlier line setting.

The decision covers the use of Enhertu (trastuzumab deruxtecan ... in England and Wales.” At the heart of the company’s concern is NICE’s use of a disease severity modifier, introduced ...

on behalf of the Pediatric Heart Failure & Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; ...

It is recommended that women with early HER2+ breast cancer receive neoadjuvant subtype-specific systemic therapy, followed by surgery. 3 Paclitaxel plus trastuzumab, docetaxel/carboplatin ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Heart failure is a major health concern, especially for aging populations—it significantly increases mortality rates, and ...

A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...